Recent blog posts
Limertinib: A Novel Third-Generation EGFR-TKI Approved in China
Drug Insights
3 min read
Limertinib: A Novel Third-Generation EGFR-TKI Approved in China
14 February 2025
Limertinib is a newly developed small-molecule chemical drug, specifically designed as an inhibitor targeting the epidermal growth factor receptor (EGFR) T790M mutation.
Read →
Senaparib: A Next-Generation PARP1/2 Inhibitor Approved in China
Drug Insights
3 min read
Senaparib: A Next-Generation PARP1/2 Inhibitor Approved in China
14 February 2025
Senaparib is a next-generation, highly potent PARP1/2 inhibitor developed by IMPACT Therapeutics.
Read →
Prusogliptin: A Novel DPP-4 Inhibitor Approved in China
Drug Insights
3 min read
Prusogliptin: A Novel DPP-4 Inhibitor Approved in China
14 February 2025
Prusogliptin, developed by CSPC Ouyi Pharmaceutical, is a novel oral dipeptidyl peptidase-4 (DPP-4) inhibitor that was approved by NMPA on January 8, 2025.
Read →
Finotonlimab: A Promising Anti-PD-1 Antibody for Solid Tumors
Drug Insights
3 min read
Finotonlimab: A Promising Anti-PD-1 Antibody for Solid Tumors
14 February 2025
Finotonlimab, developed by Sinocelltech, is a recombinant humanized anti-programmed death receptor-1 (PD-1) monoclonal antibody.
Read →
Efsubaglutide Alfa: A Novel GLP-1 Fusion Protein Revolutionizing Type 2 Diabetes
Drug Insights
3 min read
Efsubaglutide Alfa: A Novel GLP-1 Fusion Protein Revolutionizing Type 2 Diabetes
13 February 2025
Efsubaglutide Alfa received its first regulatory approval in China on January 24, 2025, from the National Medical Products Administration (NMPA).
Read →
Garadacimab: A Novel FXIIa-Targeting Monoclonal Antibody for Hereditary Angioedema
Drug Insights
3 min read
Garadacimab: A Novel FXIIa-Targeting Monoclonal Antibody for Hereditary Angioedema
13 February 2025
Garadacimab is an innovative, fully human IgG4 monoclonal antibody specifically designed to target activated Factor XII (FXIIa).
Read →
Datopotamab Deruxtecan: A Novel ADC Targeting Trop-2 for Advanced Breast Cancer
Drug Insights
4 min read
Datopotamab Deruxtecan: A Novel ADC Targeting Trop-2 for Advanced Breast Cancer
13 February 2025
Datopotamab Deruxtecan (Dato-DXd) is a Trop-2-targeting antibody-drug conjugate (ADC) developed jointly by Daiichi Sankyo and AstraZeneca.
Read →
Recaticimab: A Novel PCSK9-Targeting Monoclonal Antibody for Hypercholesterolemia
Drug Insights
3 min read
Recaticimab: A Novel PCSK9-Targeting Monoclonal Antibody for Hypercholesterolemia
13 February 2025
Recaticimab, a monoclonal antibody developed by Hengrui Medicine, was approved by the National Medical Products Administration (NMPA) in China on January 8, 2025.
Read →
Is Repotrectinib approved by the FDA?
Drug Insights
3 min read
Is Repotrectinib approved by the FDA?
7 August 2024
Repotrectinib, marketed under the brand name Augtyro, was FDA approved on November 15, 2023.
Read →
Is DefenCath approved by the FDA?
Drug Insights
3 min read
Is DefenCath approved by the FDA?
7 August 2024
DefenCath was approved by the U.S. Food and Drug Administration on November 15, 2023.
Read →
Is Adzynma approved by the FDA?
Drug Insights
3 min read
Is Adzynma approved by the FDA?
7 August 2024
Adzynma was approved by the U.S. Food and Drug Administration on November 9, 2023.
Read →
Is Ixchiq approved by the FDA?
Drug Insights
4 min read
Is Ixchiq approved by the FDA?
7 August 2024
Ixchiq, the world's first chikungunya vaccine, was approved by the U.S. Food and Drug Administration on November 9, 2023.
Read →